IJSTR

International Journal of Scientific & Technology Research

Home About Us Scope Editorial Board Blog/Latest News Contact Us
Scopus/Elsevier
(Re-evaluation in-progress)
CALL FOR PAPERS
AUTHORS
DOWNLOADS
CONTACT

IJSTR >> Volume 9 - Issue 4, April 2020 Edition



International Journal of Scientific & Technology Research  
International Journal of Scientific & Technology Research

Website: http://www.ijstr.org

ISSN 2277-8616



Hepatorenal Histological Studies On Bacterial Probiotic Treated Colitis Induced Male Albino Wistar Rats

[Full Text]

 

AUTHOR(S)

Shalini Gnanam, T., Kolanchinathan, P., Rathnakumari, P., Balasundaram, A.

 

KEYWORDS

Bacillus, colitis, DSS, histology, kidney, liver, Probiotics

 

ABSTRACT

Ulcerative colitis is an inflammatory bowel disease due to the various reasons. The available chemical therapies are curing the UC temporarily and provoking the disease with more severe aggressive form. Nowadays as an alternative measure, probiotics are used to treat UC without destroying the beneficial microflora in host. Male albino wistar rats were treated with 5% DSS for colitis induction. Histological analysis of hepatic and renal tissues of DSS colitis induced rats showed deleterious damages along with inflammation and blood vessel congestion. Group III (DSS+Probiotic) showed reformed layers with reduced inflammation in glomerulus and hepatocyte regions. This study proved that the oral administration of probiotics, cured the inflammation in DSS colitis wistar rats.

 

REFERENCES

[1] FAO/WHO, “Report of a Joint FAO/WHO expert consultation on evaluation of health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria,” World Health Organization and Food and Agriculture Organization of the United Nations, London, Ontario, Canada. 2001.
[2] V. Venugopalan, K.A. Shriner, A. Wong-Beringer, “Regulatory oversight and safety of probiotic use,” Emerg Infect Dis., vol. 16, no, 11, pp. 1661-1665, 2010.
[3] F.H. Degnan, “The US food and drug administration and probiotics: Regulatory categorization,” Clin Infect Dis, vol 46, no. S2, pp. S133-136, 2008.
[4] B.S. Sivamaruthi, “A comprehensive review on clinical outcome of probiotic and synbiotic therapy for inflammatory bowel diseases,” Asian Pac J Trop. Biomed., vol. 8, 179-186, 2018.
[5] R. Martin, C. Florian, M. Sylvie, M. Jean-Paul, V. Nathalie, S. Harry and L. Philippe, “Using murine colitis models to analyze probiotics–host interactions,” FEMS Microbiology Rev, vol. 41, pp. S49–S70, 2017.
[6] B. Liu, T. Liu, X. Wang, X. Zheng, H. Wang and L. Ma, “Effects of Guchang Capsule on Dextran Sulphate Sodium-Induced Experimental Ulcerative Colitis in Mice,” Evidence based Compl. Alt. Med., vol. 2016, 12-24, 2016.
[7] X. Xu, C. Xu and S.M. Saud, “Effect of Kuijie Granule on the Expression of TGF- 𝛽 /Smads Signaling Pathway in Patients with Ulcerative Colitis,” Evidence-based Complementary and Alternative Medicine, vol. 2016, no. 9, pp. 231-235, 2016
[8] M. Perencevich and R. Burakoff, “Use of antibiotics in the treatment of inflammatory bowel disease,” Inflammatory Bowel Dis., Vol. 12, no. 7, pp. 651–664, 2006.
[9] N.S. Nanda Kumar, R. Balamurugan, K. Jayakanthan, A. Pulimood, S. Pugazhendhi and B.S. Ramakrishna, “Probiotic administration alters the gut flora and attenuates colitis in mice administered dextran sodium sulfate,” J Gastroenter. Hepat., vol. 23, 1834–1839, 2008.
[10] E.M. Quigley, “Probiotics in the management of colonic disorders,” Curr Gastroenterol Rep, vol. 9, no. 5, pp. 434–440, 2007
[11] P.K. Randhawa, K. Singh, N. Singh, “A review on chemical induced inflammatory bowel disease models in rodents.” Korean J Physiol Pharm., vol. 18, pp. 279–288, 2014
[12] V. Uko, S. Thangada and K. Radhakrishnan, “Liver disorders in inflammatory bowel disease,” Gastroenterol. Res. Pract., vol. 2012, ID. 642923, 2012
[13] K. Wallace, A.D. Burt and M.C. Wright, “Liver fibrosis,” Biochem. J., vol. 411, no. 1, pp. 1-18, 2008.
[14] G. Ostapowicz, R.J. Fontana, F.V. Schiødt, A. Larson, T.J. Davern, S.H. Han, T.M. McCashland, A.O. Shakil, J.E. Hay, L. Hynan, J.S. Crippin, A.T. Blei, G. Samuel, J. Reisch and W.M. Lee, “U.S. Acute Liver Failure Study Group. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States,” Ann. Intern. Med., vol. 137, no. 12, pp. 947-954, 2002.
[15] N. Mumoli, M. Cei and A. Cosimi, “Drug-related hepatotoxicity,” N. Engl. J. Med., vol. 354, no. 20, pp. 2191-2193, 2006.
[16] G.L. Humason, “Animal Tissue Techniques,” W.H. Freeman, ed., San Francisco. 4th Edition, 1979
[17] V. Loren, J. Manye and M.C. Fuentes, “Comparative effect of the I3.1 probiotic formula in two animal models of colitis,” Probiotics Antimicro, vol. 9, pp. 71–80, 2016.
[18] C.S. Satish Kumar, K. Kondal Reddy and A.G. Reddy, “Protective effect of Lactobacillus plantarum 21, a probiotic on trinitrobenzenesulfonic acid-induced ulcerative colitis in rats,” Int Immunopharmacol., vol. 25, pp. 504–510, 2015.
[19] C.S. Satish Kumar, K. Kondal Reddy and G. Boobalan, “Immunomodulatory effects of Bifidobacterium bifidum 231 on trinitrobenzenesulfonic acid-induced ulcerative colitis in rats,” Res Vet Sci., vol. 110, no. 4, pp. 321-325, 2017